About us Contacts Drug interactions: 390 212
Drug search by name

Tarceva and Zegerid OTC

Determining the interaction of Tarceva and Zegerid OTC and the possibility of their joint administration.

Check result:
Tarceva <> Zegerid OTC
Relevance: 18.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using erlotinib together with omeprazole is generally not recommended. Omeprazole may interfere with the absorption of erlotinib into the bloodstream, which may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Concurrent administration of agents that increase gastric pH such as proton pump inhibitors may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption. When coadministered with omeprazole, erlotinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 61% and 46%, respectively. Time to maximum concentration (Tmax) and half-life did not change. Increasing the dose of erlotinib is unlikely to compensate for this loss of systemic exposure. Moreover, since proton pump inhibitors affect pH of the upper gastrointestinal tract for an extended period, separation of doses may not eliminate the interaction.

MANAGEMENT: The concomitant use of erlotinib with proton pump inhibitors should generally be avoided. If acid-suppression therapy is required during erlotinib treatment, an H2-receptor antagonist such as ranitidine may be considered. Available pharmacokinetic data suggest that erlotinib should be administered once a day, at least 2 hours before or 10 hours after dosing of the H2-receptor antagonist. Additionally, the lowest effective dosage of the H2-receptor antagonist should be prescribed.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52
Tarceva

Generic Name: erlotinib

Brand name: Tarceva

Synonyms: n.a.

Zegerid OTC

Generic Name: omeprazole / sodium bicarbonate

Brand name: Zegerid, Zegerid OTC

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction